Life Science News

FDA Approves Testing of Kidney Transplant Drug

Life Science Investing News

Myrecordjournal.com reported that Alexion Pharmaceuticals (NYSE:ALXN) today announced its approval from the U.S. Food and Drug Administration to test out a new drug in preventing complications in patients who reject organ transplants, specifically targeting kidney transplant patients.

Myrecordjournal.com reported that Alexion Pharmaceuticals (NYSE:ALXN) today announced its approval from the U.S. Food and Drug Administration to test out a new drug in preventing complications in patients who reject organ transplants, specifically targeting kidney transplant patients.
As quoted in the market news:

The drug, Soliris, is currently approved by the FDA to treat two extremely rare, life-threatening blood disorders, and is not approved in any country to prevent delayed graft function, or the failure of a transplanted organ to function properly in the patient’s body.

Read the full story in Myrecordjournal.com

MARKETS

Markets
TSX20541.92-87.00
TSXV618.10+4.50
DOW33761.71-129.31
S&P 5004099.18-11.90
NASD11870.88-16.57
ASX7539.00-19.10

COMMODITIES

Commodities
Gold1867.13-1.03
Silver22.15-0.12
Copper4.01-0.03
Palladium1713.170.00
Platinum1087.260.00
Oil75.55+1.44
Heating Oil2.84+0.07
Natural Gas2.55+0.10

DOWNLOAD FREE REPORTS

×